Local  ||| S:0 E:6 ||| JJ
tolerability  ||| S:6 E:19 ||| NN
and  ||| S:19 E:23 ||| CC
effectiveness  ||| S:23 E:37 ||| NN
of  ||| S:37 E:40 ||| IN
Ketospray®  ||| S:40 E:51 ||| CD
10 ||| S:51 E:53 ||| CD
%  ||| S:53 E:55 ||| NN
cutaneous  ||| S:55 E:65 ||| FW
spray  ||| S:65 E:71 ||| FW
solution  ||| S:71 E:80 ||| FW
Orally  ||| S:80 E:87 ||| FW
administrated  ||| S:87 E:101 ||| FW
nonsteroidal  ||| S:101 E:114 ||| FW
anti-inflammatory  ||| S:114 E:132 ||| JJ
drugs  ||| S:132 E:138 ||| NNS
are  ||| S:138 E:142 ||| VBP
effective  ||| S:142 E:152 ||| JJ
in  ||| S:152 E:155 ||| IN
the  ||| S:155 E:159 ||| DT
treatment  ||| S:159 E:169 ||| NN
of  ||| S:169 E:172 ||| IN
a  ||| S:172 E:174 ||| DT
variety  ||| S:174 E:182 ||| NN
of  ||| S:182 E:185 ||| IN
acute  ||| S:185 E:191 ||| JJ
and  ||| S:191 E:195 ||| CC
chronic  ||| S:195 E:203 ||| JJ
pain  ||| S:203 E:208 ||| NN
conditions  ||| S:208 E:219 ||| NNS
but  ||| S:219 E:223 ||| CC
their  ||| S:223 E:229 ||| PRP$
use  ||| S:229 E:233 ||| NN
may  ||| S:233 E:237 ||| MD
be  ||| S:237 E:240 ||| VB
associated  ||| S:240 E:251 ||| VBN
with  ||| S:251 E:256 ||| IN
serious  ||| S:256 E:264 ||| JJ
systemic  ||| S:264 E:273 ||| JJ
adverse  ||| S:273 E:281 ||| JJ
effects  ||| S:281 E:289 ||| NNS
which  ||| S:289 E:295 ||| WDT
are  ||| S:295 E:299 ||| VBP
correlated  ||| S:299 E:310 ||| VBN
with  ||| S:310 E:315 ||| IN
the  ||| S:315 E:319 ||| DT
therapeutic  ||| S:319 E:331 ||| JJ
plasma  ||| S:331 E:338 ||| NN
levels  ||| S:338 E:345 ||| NNS
of  ||| S:345 E:348 ||| IN
the  ||| S:348 E:352 ||| DT
drug ||| S:352 E:356 ||| NN
.  ||| S:356 E:358 ||| .
In  ||| S:358 E:361 ||| IN
order  ||| S:361 E:367 ||| NN
to  ||| S:367 E:370 ||| TO
minimize  ||| S:370 E:379 ||| VB
the  ||| S:379 E:383 ||| DT
incidence  ||| S:383 E:393 ||| NN
of  ||| S:393 E:396 ||| IN
drug  ||| S:396 E:401 ||| NN
related  ||| S:401 E:409 ||| VBN
systemic  ||| S:409 E:418 ||| JJ
events ||| S:418 E:424 ||| NNS
,  ||| S:424 E:426 ||| ,
topical  ||| S:426 E:434 ||| JJ
formulations  ||| S:434 E:447 ||| NNS
of  ||| S:447 E:450 ||| IN
the  ||| S:450 E:454 ||| DT
nonsteroidal  ||| S:454 E:467 ||| JJ
anti-inflammatory  ||| S:467 E:485 ||| JJ
drugs  ||| S:485 E:491 ||| NNS
have  ||| S:491 E:496 ||| VBP
been  ||| S:496 E:501 ||| VBN
developed ||| S:501 E:510 ||| VBN
.  ||| S:510 E:512 ||| .
A  ||| S:512 E:514 ||| DT
recently  ||| S:514 E:523 ||| RB
performed  ||| S:523 E:533 ||| VBN
review  ||| S:533 E:540 ||| NN
of  ||| S:540 E:543 ||| IN
the  ||| S:543 E:547 ||| DT
evidence  ||| S:547 E:556 ||| NN
from  ||| S:556 E:561 ||| IN
randomized ||| S:561 E:571 ||| NN
,  ||| S:571 E:573 ||| ,
double-blind ||| S:573 E:585 ||| NNP
,  ||| S:585 E:587 ||| ,
placebo  ||| S:587 E:595 ||| VBD
controlled  ||| S:595 E:606 ||| VBN
trials  ||| S:606 E:613 ||| NNS
with  ||| S:613 E:618 ||| IN
topically  ||| S:618 E:628 ||| NN
applied  ||| S:628 E:636 ||| VBD
NSAIDs  ||| S:636 E:643 ||| JJ
in  ||| S:643 E:646 ||| IN
the  ||| S:646 E:650 ||| DT
treatment  ||| S:650 E:660 ||| NN
of  ||| S:660 E:663 ||| IN
acute  ||| S:663 E:669 ||| JJ
pain  ||| S:669 E:674 ||| NN
confirmed  ||| S:674 E:684 ||| VBD
the  ||| S:684 E:688 ||| DT
previously  ||| S:688 E:699 ||| RB
described  ||| S:699 E:709 ||| VBN
pain  ||| S:709 E:714 ||| NN
relief  ||| S:714 E:721 ||| NN
effectiveness ||| S:721 E:734 ||| NN
.  ||| S:734 E:736 ||| .
For  ||| S:736 E:740 ||| IN
all  ||| S:740 E:744 ||| DT
topical  ||| S:744 E:752 ||| JJ
nonsteroidal  ||| S:752 E:765 ||| JJ
anti-inflammatory  ||| S:765 E:783 ||| JJ
drugs  ||| S:783 E:789 ||| NNS
combined ||| S:789 E:797 ||| VBN
,  ||| S:797 E:799 ||| ,
in  ||| S:799 E:802 ||| IN
comparison  ||| S:802 E:813 ||| NN
to  ||| S:813 E:816 ||| TO
placebo ||| S:816 E:823 ||| VB
,  ||| S:823 E:825 ||| ,
the  ||| S:825 E:829 ||| DT
number  ||| S:829 E:836 ||| NN
needed  ||| S:836 E:843 ||| VBN
to  ||| S:843 E:846 ||| TO
treat  ||| S:846 E:852 ||| VB
( ||| S:852 E:853 ||| -LRB-
NNT ||| S:853 E:856 ||| NNP
)  ||| S:856 E:858 ||| -RRB-
to  ||| S:858 E:861 ||| TO
achieve  ||| S:861 E:869 ||| VB
a  ||| S:869 E:871 ||| DT
clinically  ||| S:871 E:882 ||| JJ
meaningful  ||| S:882 E:893 ||| JJ
pain  ||| S:893 E:898 ||| NN
relief  ||| S:898 E:905 ||| NN
of  ||| S:905 E:908 ||| IN
50  ||| S:908 E:911 ||| CD
%  ||| S:911 E:913 ||| NN
was  ||| S:913 E:917 ||| VBD
4.5  ||| S:917 E:921 ||| CD
( ||| S:921 E:922 ||| -LRB-
3.9  ||| S:922 E:926 ||| CD
to  ||| S:926 E:929 ||| TO
5.3 ||| S:929 E:932 ||| CD
)  ||| S:932 E:934 ||| -RRB-
for  ||| S:934 E:938 ||| IN
treatment  ||| S:938 E:948 ||| NN
periods  ||| S:948 E:956 ||| NNS
of  ||| S:956 E:959 ||| IN
6  ||| S:959 E:961 ||| CD
to  ||| S:961 E:964 ||| TO
14  ||| S:964 E:967 ||| CD
days ||| S:967 E:971 ||| NNS
.  ||| S:971 E:973 ||| .
Local  ||| S:973 E:979 ||| JJ
skin  ||| S:979 E:984 ||| NN
reactions  ||| S:984 E:994 ||| NNS
were  ||| S:994 E:999 ||| VBD
generally  ||| S:999 E:1009 ||| RB
mild  ||| S:1009 E:1014 ||| JJ
and  ||| S:1014 E:1018 ||| CC
transient ||| S:1018 E:1027 ||| NN
,  ||| S:1027 E:1029 ||| ,
and  ||| S:1029 E:1033 ||| CC
did  ||| S:1033 E:1037 ||| VBD
not  ||| S:1037 E:1041 ||| RB
differ  ||| S:1041 E:1048 ||| VB
from  ||| S:1048 E:1053 ||| IN
placebo ||| S:1053 E:1060 ||| NN
.  ||| S:1060 E:1062 ||| .
The  ||| S:1062 E:1066 ||| DT
present  ||| S:1066 E:1074 ||| NN
is  ||| S:1074 E:1077 ||| VBZ
an  ||| S:1077 E:1080 ||| DT
observational ||| S:1080 E:1093 ||| NN
,  ||| S:1093 E:1095 ||| ,
multicenter ||| S:1095 E:1106 ||| NN
,  ||| S:1106 E:1108 ||| ,
open-label ||| S:1108 E:1118 ||| NNP
,  ||| S:1118 E:1120 ||| ,
non-interventional ||| S:1120 E:1138 ||| NNP
,  ||| S:1138 E:1140 ||| ,
post-authorization  ||| S:1140 E:1159 ||| JJ
safety  ||| S:1159 E:1166 ||| NN
study  ||| S:1166 E:1172 ||| NN
as  ||| S:1172 E:1175 ||| IN
it  ||| S:1175 E:1178 ||| PRP
is  ||| S:1178 E:1181 ||| VBZ
defined  ||| S:1181 E:1189 ||| VBN
by  ||| S:1189 E:1192 ||| IN
Article  ||| S:1192 E:1200 ||| NNP
21  ||| S:1200 E:1203 ||| CD
of  ||| S:1203 E:1206 ||| IN
the  ||| S:1206 E:1210 ||| DT
European  ||| S:1210 E:1219 ||| NNP
Clinical  ||| S:1219 E:1228 ||| NNP
Trials  ||| S:1228 E:1235 ||| NNP
Directive  ||| S:1235 E:1245 ||| NNP
2001 ||| S:1245 E:1249 ||| CD
/ ||| S:1249 E:1250 ||| CD
20 ||| S:1250 E:1252 ||| CD
/ ||| S:1252 E:1253 ||| CD
EC ||| S:1253 E:1255 ||| NNP
.  ||| S:1255 E:1257 ||| .
The  ||| S:1257 E:1261 ||| DT
main  ||| S:1261 E:1266 ||| JJ
objective  ||| S:1266 E:1276 ||| NN
of  ||| S:1276 E:1279 ||| IN
this  ||| S:1279 E:1284 ||| DT
study  ||| S:1284 E:1290 ||| NN
was  ||| S:1290 E:1294 ||| VBD
to  ||| S:1294 E:1297 ||| TO
evaluate  ||| S:1297 E:1306 ||| VB
the  ||| S:1306 E:1310 ||| DT
local  ||| S:1310 E:1316 ||| JJ
tolerability  ||| S:1316 E:1329 ||| NN
and  ||| S:1329 E:1333 ||| CC
the  ||| S:1333 E:1337 ||| DT
therapeutic  ||| S:1337 E:1349 ||| JJ
efficacy  ||| S:1349 E:1358 ||| NN
of  ||| S:1358 E:1361 ||| IN
static  ||| S:1361 E:1368 ||| JJ
and  ||| S:1368 E:1372 ||| CC
pain  ||| S:1372 E:1377 ||| NN
on  ||| S:1377 E:1380 ||| IN
movement  ||| S:1380 E:1389 ||| NN
intensity  ||| S:1389 E:1399 ||| NN
reduction  ||| S:1399 E:1409 ||| NN
of  ||| S:1409 E:1412 ||| IN
Ketospray®  ||| S:1412 E:1423 ||| CD
10 ||| S:1423 E:1425 ||| CD
%  ||| S:1425 E:1427 ||| NN
cutaneous  ||| S:1427 E:1437 ||| NN
spray  ||| S:1437 E:1443 ||| NN
solution  ||| S:1443 E:1452 ||| NN
administered  ||| S:1452 E:1465 ||| VBN
in  ||| S:1465 E:1468 ||| IN
accordance  ||| S:1468 E:1479 ||| NN
with  ||| S:1479 E:1484 ||| IN
the  ||| S:1484 E:1488 ||| DT
terms  ||| S:1488 E:1494 ||| NNS
of  ||| S:1494 E:1497 ||| IN
the  ||| S:1497 E:1501 ||| DT
marketing  ||| S:1501 E:1511 ||| NN
authorization  ||| S:1511 E:1525 ||| NN
and  ||| S:1525 E:1529 ||| CC
last  ||| S:1529 E:1534 ||| JJ
version  ||| S:1534 E:1542 ||| NN
of  ||| S:1542 E:1545 ||| IN
summary  ||| S:1545 E:1553 ||| NN
of  ||| S:1553 E:1556 ||| IN
product  ||| S:1556 E:1564 ||| NN
characteristics  ||| S:1564 E:1580 ||| NNS
approved  ||| S:1580 E:1589 ||| VBN
by  ||| S:1589 E:1592 ||| IN
National  ||| S:1592 E:1601 ||| NNP
Medicines  ||| S:1601 E:1611 ||| NNP
Agency  ||| S:1611 E:1618 ||| NNP
of  ||| S:1618 E:1621 ||| IN
Romania ||| S:1621 E:1628 ||| NNP
.  ||| S:1628 E:1630 ||| .
In  ||| S:1630 E:1633 ||| IN
compliance  ||| S:1633 E:1644 ||| NN
with  ||| S:1644 E:1649 ||| IN
the  ||| S:1649 E:1653 ||| DT
Post-marketing  ||| S:1653 E:1668 ||| JJ
study  ||| S:1668 E:1674 ||| NN
type ||| S:1674 E:1678 ||| NN
,  ||| S:1678 E:1680 ||| ,
the  ||| S:1680 E:1684 ||| DT
assignment  ||| S:1684 E:1695 ||| NN
of  ||| S:1695 E:1698 ||| IN
the  ||| S:1698 E:1702 ||| DT
patient  ||| S:1702 E:1710 ||| NN
to  ||| S:1710 E:1713 ||| TO
a  ||| S:1713 E:1715 ||| DT
particular  ||| S:1715 E:1726 ||| JJ
therapeutic  ||| S:1726 E:1738 ||| JJ
strategy  ||| S:1738 E:1747 ||| NN
fell  ||| S:1747 E:1752 ||| VBD
within  ||| S:1752 E:1759 ||| IN
current  ||| S:1759 E:1767 ||| JJ
practice ||| S:1767 E:1775 ||| NN
.  ||| S:1775 E:1777 ||| .
The  ||| S:1777 E:1781 ||| DT
prescription  ||| S:1781 E:1794 ||| NN
of  ||| S:1794 E:1797 ||| IN
the  ||| S:1797 E:1801 ||| DT
medicine  ||| S:1801 E:1810 ||| NN
was  ||| S:1810 E:1814 ||| VBD
not  ||| S:1814 E:1818 ||| RB
subject  ||| S:1818 E:1826 ||| JJ
to  ||| S:1826 E:1829 ||| TO
compliance  ||| S:1829 E:1840 ||| NN
with  ||| S:1840 E:1845 ||| IN
predefined  ||| S:1845 E:1856 ||| JJ
patients ||| S:1856 E:1864 ||| NNS
'  ||| S:1864 E:1866 ||| POS
characteristics ||| S:1866 E:1881 ||| NNS
.  ||| S:1881 E:1883 ||| .
No  ||| S:1883 E:1886 ||| DT
specific ||| S:1886 E:1894 ||| JJ
,  ||| S:1894 E:1896 ||| ,
out  ||| S:1896 E:1900 ||| RB
of  ||| S:1900 E:1903 ||| IN
the  ||| S:1903 E:1907 ||| DT
daily  ||| S:1907 E:1913 ||| JJ
practice  ||| S:1913 E:1922 ||| NN
routine  ||| S:1922 E:1930 ||| JJ
diagnostic ||| S:1930 E:1940 ||| NN
,  ||| S:1940 E:1942 ||| ,
monitoring ||| S:1942 E:1952 ||| NN
,  ||| S:1952 E:1954 ||| ,
instrumental  ||| S:1954 E:1967 ||| JJ
or  ||| S:1967 E:1970 ||| CC
laboratory  ||| S:1970 E:1981 ||| NN
assessments  ||| S:1981 E:1993 ||| NNS
were  ||| S:1993 E:1998 ||| VBD
foreseen  ||| S:1998 E:2007 ||| VBN
by  ||| S:2007 E:2010 ||| IN
the  ||| S:2010 E:2014 ||| DT
study  ||| S:2014 E:2020 ||| NN
protocol ||| S:2020 E:2028 ||| NN
.  ||| S:2028 E:2030 ||| .
Patients ||| S:2030 E:2038 ||| NNS
'  ||| S:2038 E:2040 ||| POS
data  ||| S:2040 E:2045 ||| NNS
were  ||| S:2045 E:2050 ||| VBD
collected  ||| S:2050 E:2060 ||| VBN
into  ||| S:2060 E:2065 ||| IN
respective  ||| S:2065 E:2076 ||| JJ
case  ||| S:2076 E:2081 ||| NN
report  ||| S:2081 E:2088 ||| NN
forms ||| S:2088 E:2093 ||| NNS
.  ||| S:2093 E:2095 ||| .
Study  ||| S:2095 E:2101 ||| NN
medication ||| S:2101 E:2111 ||| NN
,  ||| S:2111 E:2113 ||| ,
Ketoprofen  ||| S:2113 E:2124 ||| NNP
10 ||| S:2124 E:2126 ||| CD
%  ||| S:2126 E:2128 ||| NN
Cutaneous  ||| S:2128 E:2138 ||| NNP
Spray  ||| S:2138 E:2144 ||| NNP
Solution  ||| S:2144 E:2153 ||| NNP
was  ||| S:2153 E:2157 ||| VBD
administered  ||| S:2157 E:2170 ||| VBN
to  ||| S:2170 E:2173 ||| TO
the  ||| S:2173 E:2177 ||| DT
affected  ||| S:2177 E:2186 ||| JJ
area  ||| S:2186 E:2191 ||| NN
at  ||| S:2191 E:2194 ||| IN
the  ||| S:2194 E:2198 ||| DT
dose  ||| S:2198 E:2203 ||| NN
of  ||| S:2203 E:2206 ||| IN
3-6  ||| S:2206 E:2210 ||| CD
spray  ||| S:2210 E:2216 ||| NN
puffs ||| S:2216 E:2221 ||| NN
,  ||| S:2221 E:2223 ||| ,
2-3  ||| S:2223 E:2227 ||| CD
times  ||| S:2227 E:2233 ||| NNS
a  ||| S:2233 E:2235 ||| DT
day ||| S:2235 E:2238 ||| NN
,  ||| S:2238 E:2240 ||| ,
for  ||| S:2240 E:2244 ||| IN
7  ||| S:2244 E:2246 ||| CD
days ||| S:2246 E:2250 ||| NNS
.  ||| S:2250 E:2252 ||| .
According  ||| S:2252 E:2262 ||| VBG
to  ||| S:2262 E:2265 ||| TO
the  ||| S:2265 E:2269 ||| DT
study  ||| S:2269 E:2275 ||| NN
type ||| S:2275 E:2279 ||| NN
,  ||| S:2279 E:2281 ||| ,
descriptive  ||| S:2281 E:2293 ||| JJ
statistical  ||| S:2293 E:2305 ||| JJ
methods  ||| S:2305 E:2313 ||| NNS
were  ||| S:2313 E:2318 ||| VBD
applied ||| S:2318 E:2325 ||| VBN
.  ||| S:2325 E:2327 ||| .
Since  ||| S:2327 E:2333 ||| IN
almost  ||| S:2333 E:2340 ||| RB
half  ||| S:2340 E:2345 ||| NN
of  ||| S:2345 E:2348 ||| IN
the  ||| S:2348 E:2352 ||| DT
patients  ||| S:2352 E:2361 ||| NNS
were  ||| S:2361 E:2366 ||| VBD
treated  ||| S:2366 E:2374 ||| VBN
with  ||| S:2374 E:2379 ||| IN
combination  ||| S:2379 E:2391 ||| NN
of  ||| S:2391 E:2394 ||| IN
the  ||| S:2394 E:2398 ||| DT
pain  ||| S:2398 E:2403 ||| NN
relieving  ||| S:2403 E:2413 ||| NN
medications ||| S:2413 E:2424 ||| NN
,  ||| S:2424 E:2426 ||| ,
sizing  ||| S:2426 E:2433 ||| VBG
of  ||| S:2433 E:2436 ||| IN
the  ||| S:2436 E:2440 ||| DT
pain  ||| S:2440 E:2445 ||| NN
relieving  ||| S:2445 E:2455 ||| NN
effects ||| S:2455 E:2462 ||| NNS
,  ||| S:2462 E:2464 ||| ,
as  ||| S:2464 E:2467 ||| IN
NNT ||| S:2467 E:2470 ||| NNP
,  ||| S:2470 E:2472 ||| ,
between  ||| S:2472 E:2480 ||| IN
the  ||| S:2480 E:2484 ||| DT
two  ||| S:2484 E:2488 ||| CD
groups  ||| S:2488 E:2495 ||| NNS
was  ||| S:2495 E:2499 ||| VBD
made ||| S:2499 E:2503 ||| VBN
.  ||| S:2503 E:2505 ||| .
There  ||| S:2505 E:2511 ||| EX
were  ||| S:2511 E:2516 ||| VBD
2020  ||| S:2516 E:2521 ||| CD
study  ||| S:2521 E:2527 ||| NN
subjects  ||| S:2527 E:2536 ||| NNS
in  ||| S:2536 E:2539 ||| IN
safety  ||| S:2539 E:2546 ||| NN
and  ||| S:2546 E:2550 ||| CC
ITT  ||| S:2550 E:2554 ||| NNP
analysis  ||| S:2554 E:2563 ||| NN
population  ||| S:2563 E:2574 ||| NN
and  ||| S:2574 E:2578 ||| CC
1802  ||| S:2578 E:2583 ||| CD
( ||| S:2583 E:2584 ||| -LRB-
89 ||| S:2584 E:2586 ||| CD
% ||| S:2586 E:2587 ||| NN
)  ||| S:2587 E:2589 ||| -RRB-
in  ||| S:2589 E:2592 ||| IN
PP  ||| S:2592 E:2595 ||| NNP
efficacy  ||| S:2595 E:2604 ||| JJ
analysis  ||| S:2604 E:2613 ||| NN
population ||| S:2613 E:2623 ||| NN
.  ||| S:2623 E:2625 ||| .
There  ||| S:2625 E:2631 ||| EX
were  ||| S:2631 E:2636 ||| VBD
4  ||| S:2636 E:2638 ||| CD
types  ||| S:2638 E:2644 ||| NNS
of  ||| S:2644 E:2647 ||| IN
injuries ||| S:2647 E:2655 ||| NNS
:  ||| S:2655 E:2657 ||| :
non-complicated  ||| S:2657 E:2673 ||| NNP
strain-sprain  ||| S:2673 E:2687 ||| NNP
( ||| S:2687 E:2688 ||| -LRB-
555 ||| S:2688 E:2691 ||| CD
) ||| S:2691 E:2692 ||| -RRB-
,  ||| S:2692 E:2694 ||| ,
soft  ||| S:2694 E:2699 ||| JJ
tissue  ||| S:2699 E:2706 ||| NN
contusion  ||| S:2706 E:2716 ||| NNS
( ||| S:2716 E:2717 ||| -LRB-
323 ||| S:2717 E:2720 ||| CD
) ||| S:2720 E:2721 ||| -RRB-
,  ||| S:2721 E:2723 ||| ,
low  ||| S:2723 E:2727 ||| JJ
back  ||| S:2727 E:2732 ||| JJ
pain  ||| S:2732 E:2737 ||| NN
( ||| S:2737 E:2738 ||| -LRB-
461 ||| S:2738 E:2741 ||| CD
)  ||| S:2741 E:2743 ||| -RRB-
and  ||| S:2743 E:2747 ||| CC
osteoarthritis  ||| S:2747 E:2762 ||| NNS
( ||| S:2762 E:2763 ||| -LRB-
681  ||| S:2763 E:2767 ||| CD
patients ||| S:2767 E:2775 ||| NNS
) ||| S:2775 E:2776 ||| -RRB-
.  ||| S:2776 E:2778 ||| .
Ten  ||| S:2778 E:2782 ||| CD
patients  ||| S:2782 E:2791 ||| NNS
reported  ||| S:2791 E:2800 ||| VBD
13  ||| S:2800 E:2803 ||| CD
side  ||| S:2803 E:2808 ||| NN
effects  ||| S:2808 E:2816 ||| NNS
of  ||| S:2816 E:2819 ||| IN
which  ||| S:2819 E:2825 ||| WDT
10  ||| S:2825 E:2828 ||| CD
were  ||| S:2828 E:2833 ||| VBD
recognized  ||| S:2833 E:2844 ||| VBN
by  ||| S:2844 E:2847 ||| IN
investigators  ||| S:2847 E:2861 ||| NNS
as  ||| S:2861 E:2864 ||| IN
adverse  ||| S:2864 E:2872 ||| JJ
drug  ||| S:2872 E:2877 ||| NN
reactions ||| S:2877 E:2886 ||| NNS
.  ||| S:2886 E:2888 ||| .
All  ||| S:2888 E:2892 ||| DT
side  ||| S:2892 E:2897 ||| NN
effects  ||| S:2897 E:2905 ||| NNS
were  ||| S:2905 E:2910 ||| VBD
non-serious ||| S:2910 E:2921 ||| JJ
,  ||| S:2921 E:2923 ||| ,
listed ||| S:2923 E:2929 ||| VBN
,  ||| S:2929 E:2931 ||| ,
application  ||| S:2931 E:2943 ||| NN
site  ||| S:2943 E:2948 ||| NN
skin  ||| S:2948 E:2953 ||| NN
changes ||| S:2953 E:2960 ||| NNS
.  ||| S:2960 E:2962 ||| .
Remarkable  ||| S:2962 E:2973 ||| JJ
reductions  ||| S:2973 E:2984 ||| NNS
of  ||| S:2984 E:2987 ||| IN
static  ||| S:2987 E:2994 ||| JJ
and  ||| S:2994 E:2998 ||| CC
pain  ||| S:2998 E:3003 ||| NN
on  ||| S:3003 E:3006 ||| IN
movement  ||| S:3006 E:3015 ||| NN
intensity  ||| S:3015 E:3025 ||| NN
were  ||| S:3025 E:3030 ||| VBD
experienced  ||| S:3030 E:3042 ||| VBN
by  ||| S:3042 E:3045 ||| IN
patients  ||| S:3045 E:3054 ||| NNS
irrespective  ||| S:3054 E:3067 ||| RB
of  ||| S:3067 E:3070 ||| IN
the  ||| S:3070 E:3074 ||| DT
type  ||| S:3074 E:3079 ||| NN
of  ||| S:3079 E:3082 ||| IN
the  ||| S:3082 E:3086 ||| DT
injury  ||| S:3086 E:3093 ||| NN
and  ||| S:3093 E:3097 ||| CC
the  ||| S:3097 E:3101 ||| DT
type  ||| S:3101 E:3106 ||| NN
of  ||| S:3106 E:3109 ||| IN
the  ||| S:3109 E:3113 ||| DT
treatment ||| S:3113 E:3122 ||| NN
.  ||| S:3122 E:3124 ||| .
However ||| S:3124 E:3131 ||| RB
,  ||| S:3131 E:3133 ||| ,
a  ||| S:3133 E:3135 ||| DT
clinically  ||| S:3135 E:3146 ||| JJ
meaningful  ||| S:3146 E:3157 ||| JJ
benefit  ||| S:3157 E:3165 ||| NN
of  ||| S:3165 E:3168 ||| IN
the  ||| S:3168 E:3172 ||| DT
concomitantly  ||| S:3172 E:3186 ||| JJ
prescribed  ||| S:3186 E:3197 ||| JJ
pain  ||| S:3197 E:3202 ||| NN
relieving  ||| S:3202 E:3212 ||| NN
medications  ||| S:3212 E:3224 ||| NNS
was  ||| S:3224 E:3228 ||| VBD
not  ||| S:3228 E:3232 ||| RB
observed  ||| S:3232 E:3241 ||| VBN
for  ||| S:3241 E:3245 ||| IN
any  ||| S:3245 E:3249 ||| DT
type  ||| S:3249 E:3254 ||| NN
of  ||| S:3254 E:3257 ||| IN
pain ||| S:3257 E:3261 ||| NN
.  ||| S:3261 E:3263 ||| .
The  ||| S:3263 E:3267 ||| DT
lowest  ||| S:3267 E:3274 ||| JJS
NNT  ||| S:3274 E:3278 ||| NNP
( ||| S:3278 E:3279 ||| -LRB-
14 ||| S:3279 E:3281 ||| CD
)  ||| S:3281 E:3283 ||| -RRB-
was  ||| S:3283 E:3287 ||| VBD
obtained  ||| S:3287 E:3296 ||| VBN
for  ||| S:3296 E:3300 ||| IN
the  ||| S:3300 E:3304 ||| DT
reduction  ||| S:3304 E:3314 ||| NN
of  ||| S:3314 E:3317 ||| IN
pain  ||| S:3317 E:3322 ||| NN
at  ||| S:3322 E:3325 ||| IN
rest  ||| S:3325 E:3330 ||| NN
in  ||| S:3330 E:3333 ||| IN
patients  ||| S:3333 E:3342 ||| NNS
with  ||| S:3342 E:3347 ||| IN
strain-sprain  ||| S:3347 E:3361 ||| JJ
or  ||| S:3361 E:3364 ||| CC
soft  ||| S:3364 E:3369 ||| JJ
tissue  ||| S:3369 E:3376 ||| NN
contusions ||| S:3376 E:3386 ||| NN
.  ||| S:3386 E:3388 ||| .
The  ||| S:3388 E:3392 ||| DT
highest  ||| S:3392 E:3400 ||| JJS
NNT  ||| S:3400 E:3404 ||| NNP
( ||| S:3404 E:3405 ||| -LRB-
283 ||| S:3405 E:3408 ||| LS
)  ||| S:3408 E:3410 ||| -RRB-
was  ||| S:3410 E:3414 ||| VBD
for  ||| S:3414 E:3418 ||| IN
pain  ||| S:3418 E:3423 ||| NN
at  ||| S:3423 E:3426 ||| IN
rest  ||| S:3426 E:3431 ||| NN
in  ||| S:3431 E:3434 ||| IN
patients  ||| S:3434 E:3443 ||| NNS
treated  ||| S:3443 E:3451 ||| VBN
for  ||| S:3451 E:3455 ||| IN
the  ||| S:3455 E:3459 ||| DT
exacerbation  ||| S:3459 E:3472 ||| NN
of  ||| S:3472 E:3475 ||| IN
the  ||| S:3475 E:3479 ||| DT
chronic  ||| S:3479 E:3487 ||| JJ
pain ||| S:3487 E:3491 ||| NN
.  ||| S:3491 E:3493 ||| .
The  ||| S:3493 E:3497 ||| DT
results  ||| S:3497 E:3505 ||| NNS
of  ||| S:3505 E:3508 ||| IN
the  ||| S:3508 E:3512 ||| DT
current  ||| S:3512 E:3520 ||| JJ
post-authorization  ||| S:3520 E:3539 ||| JJ
study  ||| S:3539 E:3545 ||| NN
confirm  ||| S:3545 E:3553 ||| VBP
beneficial  ||| S:3553 E:3564 ||| JJ
pain  ||| S:3564 E:3569 ||| NN
intensity  ||| S:3569 E:3579 ||| NN
reducing  ||| S:3579 E:3588 ||| VBG
efficacy  ||| S:3588 E:3597 ||| NN
of  ||| S:3597 E:3600 ||| IN
Ketospray  ||| S:3600 E:3610 ||| NNP
10 ||| S:3610 E:3612 ||| CD
%  ||| S:3612 E:3614 ||| NN
associated  ||| S:3614 E:3625 ||| VBN
with  ||| S:3625 E:3630 ||| IN
good  ||| S:3630 E:3635 ||| JJ
local  ||| S:3635 E:3641 ||| JJ
tolerability  ||| S:3641 E:3654 ||| NN
of  ||| S:3654 E:3657 ||| IN
7  ||| S:3657 E:3659 ||| CD
days  ||| S:3659 E:3664 ||| NNS
treatment  ||| S:3664 E:3674 ||| NN
course ||| S:3674 E:3680 ||| NN
.  ||| S:3680 E:3682 ||| .
Concomitant  ||| S:3682 E:3694 ||| JJ
administration  ||| S:3694 E:3709 ||| NN
of  ||| S:3709 E:3712 ||| IN
systemic  ||| S:3712 E:3721 ||| JJ
pain  ||| S:3721 E:3726 ||| NN
relieving  ||| S:3726 E:3736 ||| NN
medication  ||| S:3736 E:3747 ||| NN
did  ||| S:3747 E:3751 ||| VBD
not  ||| S:3751 E:3755 ||| RB
substantially  ||| S:3755 E:3769 ||| RB
contribute  ||| S:3769 E:3780 ||| VB
neither  ||| S:3780 E:3788 ||| RB
to  ||| S:3788 E:3791 ||| TO
the  ||| S:3791 E:3795 ||| DT
relief  ||| S:3795 E:3802 ||| NN
of  ||| S:3802 E:3805 ||| IN
pain  ||| S:3805 E:3810 ||| NN
at  ||| S:3810 E:3813 ||| IN
rest  ||| S:3813 E:3818 ||| NN
nor  ||| S:3818 E:3822 ||| CC
of  ||| S:3822 E:3825 ||| IN
pain  ||| S:3825 E:3830 ||| NN
on  ||| S:3830 E:3833 ||| IN
movement  ||| S:3833 E:3842 ||| NN
among  ||| S:3842 E:3848 ||| IN
the  ||| S:3848 E:3852 ||| DT
subjects  ||| S:3852 E:3861 ||| NNS
of  ||| S:3861 E:3864 ||| IN
respective  ||| S:3864 E:3875 ||| JJ
study  ||| S:3875 E:3881 ||| NN
populations ||| S:3881 E:3892 ||| NNS
.  ||| S:3892 E:3894 ||| .
